Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

IOVA anticipates successful FDA review for lifileucel and strategic acquisition

IOVA's Q1 2023 earnings call highlighted significant progress in TIL therapy pipeline, commercial launch preparations, and financial performance. The company is well-positioned for FDA review of lifileucel and is strategically acquiring Proleukin to support TIL therapy.

IOVA anticipates lifileucel launch after strong Q2 performance

IOVA's Q2 2023 earnings call highlighted the company's strong performance, robust preparations for the lifileucel launch, and the challenges and opportunities it faces in the evolving landscape of oncology studies and commercialization. The company's positive outlook and strategic initiatives position it for future success, while also acknowledging the need to address enrollment challenges and manage financial expectations.

IOVA reports strong Q3 earnings and progresses in global expansion

IOVA's Q3 2023 performance reflects strong financials, progress in clinical trials, and a focus on driving revenues while managing expenses. The company faces challenges related to regulatory processes and competitive benchmarks but has opportunities for international expansion and cost reduction. Overall, IOVA's strategic priorities and promising long-term data position it for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)---- $IOVA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors

86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting

In a brief statement, Iovance Biotherapeutics Inc (NASDAQ: IOVA) company divulged that the FDA wants to see more data on the assays used to ensure each batch of its tumor-infiltrating lymphocyte therapy (TIL) is up to standard, in addition to what was already submitted. This FDA holdup pushed the submission of the lifileucel marketing application for melanoma in the first half of 2022, which amounts to a delay of more than a year from the original timeline of submitting in 2020.

Additional Assay Data Holdup Delays Iovance's Lifileucel Filing Again, CEO Resigns; Shares Plunge

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has received regulatory feedback from the FDA on its potency assays for lifileucel. Following FDA feedback, Iovance will have to submit additional assay data and meet with the FDA in the second half of 2021.

Iovance's Lifileucel US Application Submission Pushed To 2022

SAN CARLOS, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced receipt of regulatory feedback from the U.S. Food and Drug Administration (FDA) regarding its potency assays for lifileucel. Previously, the company reported the submission of assay data to the FDA and recently the FDA provided comments regarding the data package.

Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays

Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up

Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic Melanoma

Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.

Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q1 2021 Results - Earnings Call Transcript

Expanding First-in-Class TIL Cell Therapy Platform for Solid Tumors Expanding First-in-Class TIL Cell Therapy Platform for Solid Tumors

Iovance Biotherapeutics Reports First Quarter 2021 Financial Results and Corporate Updates

Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study

Iovance Biotherapeutics to Present Clinical Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting

SAN CARLOS, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 6, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 6, 2021

Buying stocks in a bear market necessitates courage, as you need to overcome your fear. Conquering your fear to purchase during a down cycle usually leads to outsized returns.

Iovance Biotherapeutics: The Frontier Of Novel Cancer Treatment

Median Duration of Response Not Reached at 28.1 Months  of Median Study Follow Up in Cohort 2 of C-144-01 Study

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting

TIL therapy looks able to win a large addressable market, and Iovance is the leader of the pack.

This Big Leap in Cancer Treatment Could Change the Landscape

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

Why Is Iovance Biotherapeutics (IOVA) Down 21.5% Since Last Earnings Report?

Bristol-Myers

Eli Lilly

The prospects for several drug makers—and their investors—are likely to be affected as clinical trial results for key medications are reported this year.

Eli Lilly, Bristol-Myers and Iovance Await Important Drug Trial Results

Today, we revisit oncology concern Iovance Biotherapeutics for the first time in years after a recent dip in its share price.

Revisiting Iovance Biotherapeutics After The Dip

SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky, Ph.D., as Chief Operating Officer, effective today. Dr. Bilinsky brings more than 20 years of biotechnology industry experience as a senior executive and consultant, including public companies.

Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer

SAN CARLOS, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that long-term interim data from Cohort 2 in the C-144-01 clinical study (NCT02360579) in advanced melanoma has been accepted as an oral presentation in a Clinical Trials Plenary Session at the upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting.

Iovance Biotherapeutics to Present Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at American Association for Cancer Research (AACR) 2021 Annual Meeting

Bumble

NextEra Energy

Wheaton Precious Metals

Akebia Therapeutics

Aravive Inc

BeiGene

Imperial Oil

loanDepot

With the trading day about halfway over, the broad markets were pushing higher on the day.

Bumble, NextEra Energy, Wheaton Precious Metals and More Monday Afternoon Analyst Calls

SAN CARLOS, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcare conferences:

Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.

Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2020 Results - Earnings Call Transcript

Advancing First-in-Class TIL Cell Therapy for Solid Tumors Advancing First-in-Class TIL Cell Therapy for Solid Tumors

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates

SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EST.

News for Iovance Biotherapeutics Stock (IOVA)